More
CM310 was granted Breakthrough Therapy Designation by the CDE for the treatment of moderate to severe atopic dermatitis
CHENGDU, China, June 15, 2022 – Keymed Biosciences (HKEX: 02162) is pleased to announce that the Center for Drug Eval
2022-06-15